Pre-clinical

Ebixa is a moderate affinity, uncompetitive NMDA receptor antagonist.

In this section you can explore the unique features of Ebixa. Click on your area of interest from the list below to read more.

Mechanism of action of memantine

Johnson JW, Kotermanski SE Curr Opin Pharmacol 2006; 6(1):61-67

Neuroprotective and Symptomatological Action of Memantine Relevant for Alzheimer’s Disease - A Unified Glutamatergic Hypothesis on the Mechanism of Action

Wojciech Danysz, Chris G. Parsons, Hans-Jörg Möbius Albrecht Stöffler and Günter Quack,. Department of Pharmacology, Merz+Co., Eckenheimer Landstrasse 100-104 60318 Frankfurt/Main, FRG

Neuroanatomy/pathology and the interplay of neurotransmitters in moderate to severe Alzheimer disease

Paul T. Francis, PhD., From the Wolfson Centre for Age-Related Diseases and the GKT School of Biomedical Science, King’s College London, London, England.

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

Parsons CG, Danysz W, Quack G., Department of Pharmacological Research, Merz and Co., Frankfurt am Main, Germany.

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

Rogawski MA, Wenk GL,. CNS Drug Rev 2003; 9(3):275-308.

Last updated: 03.09.2007

Key publications

Clinical publications

Pre-clinical

Literature Search

PubMed
Google Scholar